Reuters logo
BRIEF-Selexis and OSE Immunotherapeutics expand strategic alliance
September 26, 2017 / 6:22 AM / in 23 days

BRIEF-Selexis and OSE Immunotherapeutics expand strategic alliance

Sept 26 (Reuters) - OSE IMMUNOTHERAPEUTICS SA:

* SELEXIS SA AND OSE IMMUNOTHERAPEUTICS EXPAND STRATEGIC ALLIANCE TO FURTHER ADVANCE OSE’S OSE-172 AND OSE-703 CANCER IMMUNOTHERAPY PROGRAMS

* ‍2ND AND 3RD COMMERCIAL LICENSE AGREEMENTS BETWEEN PARTNERS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below